Dr. Reddys Laboratories is currently trading at Rs. 2418.50, up by 11.65 points or 0.48% from its previous closing of Rs. 2406.85 on the BSE.
The scrip opened at Rs. 2411.00 and has touched a high and low of Rs. 2438.05 and Rs. 2406.15 respectively. So far 14999 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2687.45 on 28-Sep-2018 and a 52 week low of Rs. 1888.00 on 21-May-2018.
Last one week high and low of the scrip stood at Rs. 2475.00 and Rs. 2392.45 respectively. The current market cap of the company is Rs. 40208.00 crore.
The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 44.66% and 14.73% respectively.
The Regulatory Authority of Germany (Regierung von Oberbayern) has concluded the follow-on audit of Dr. Reddy’s Laboratories’ Formulations manufacturing facility in
Duvvada, Vishakapatnam, on November 09, 2018. The facility is considered compliant and the EU-GMP certification continues to remain active with one specific exclusion of a new product. The company will be submitting a detailed Corrective and Preventive Action Plan (CAPA) to the authorities.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1464.85 |
Dr. Reddys Lab | 5955.65 |
Cipla | 1477.15 |
Zydus Lifesciences | 1050.35 |
Lupin | 1603.55 |
View more.. |